Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD 360324

Drug Profile

PD 360324

Alternative Names: PD-0360324; PD-360,324

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Cutaneous lupus erythematosus; Pulmonary sarcoidosis; Rheumatoid arthritis

Most Recent Events

  • 09 Jan 2020 PD 360324 is still in phase II trials for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA, United Kingdom, Australia, Canada, France, Germany, Netherlands, Japan (IV) (NCT02554812) (EudraCT2015-002552-27)
  • 12 Mar 2019 M.D. Anderson Cancer Center withdraws a phase II trial for Ovarian, Peritoneal and Fallopian tube cancer (Second-line therapy or greater) prior enrolment in USA (NCT02948101)
  • 06 Nov 2014 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA, Canada & Moldova (IV)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top